Agios Pharmaceuticals, Inc. (AGIO)
33.10
-0.03
(-0.09%)
USD |
NASDAQ |
Sep 04, 16:00
33.08
-0.02
(-0.06%)
After-Hours: 20:00
Agios Pharmaceuticals SG&A Expense (TTM) : 192.74M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 192.74M |
| March 31, 2026 | 187.06M |
| December 31, 2025 | 180.28M |
| September 30, 2025 | 180.37M |
| June 30, 2025 | 177.63M |
| March 31, 2025 | 167.30M |
| December 31, 2024 | 156.78M |
| September 30, 2024 | 140.39M |
| June 30, 2024 | 127.68M |
| March 31, 2024 | 122.55M |
| December 31, 2023 | 119.90M |
| September 30, 2023 | 117.37M |
| June 30, 2023 | 120.67M |
| March 31, 2023 | 118.52M |
| December 31, 2022 | 121.67M |
| September 30, 2022 | 120.43M |
| June 30, 2022 | 118.46M |
| March 31, 2022 | 119.41M |
| December 31, 2021 | 121.44M |
| September 30, 2021 | 115.83M |
| June 30, 2021 | 117.02M |
| March 31, 2021 | 116.98M |
| December 31, 2020 | 115.11M |
| September 30, 2020 | 124.03M |
| June 30, 2020 | 128.70M |
| Date | Value |
|---|---|
| March 31, 2020 | 131.92M |
| December 31, 2019 | 132.03M |
| September 30, 2019 | 129.06M |
| June 30, 2019 | 127.14M |
| March 31, 2019 | 121.39M |
| December 31, 2018 | 114.14M |
| September 30, 2018 | 105.00M |
| June 30, 2018 | 91.35M |
| March 31, 2018 | 80.85M |
| December 31, 2017 | 71.12M |
| September 30, 2017 | 63.79M |
| June 30, 2017 | 58.19M |
| March 31, 2017 | 54.70M |
| December 31, 2016 | 50.71M |
| September 30, 2016 | 45.52M |
| June 30, 2016 | 43.59M |
| March 31, 2016 | 39.88M |
| December 31, 2015 | 35.99M |
| September 30, 2015 | 32.31M |
| June 30, 2015 | 27.55M |
| March 31, 2015 | 22.78M |
| December 31, 2014 | 19.12M |
| September 30, 2014 | 16.33M |
| June 30, 2014 | 13.69M |
| March 31, 2014 | 11.36M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Biogen, Inc. | 2.594B |
| Insmed, Inc. | 893.58M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Regeneron Pharmaceuticals, Inc. | 2.743B |